Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JY231 in active SLE
NCT06675422Phase 2Recruiting
- Start
- Oct 2024
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of JY231 in systemic lupus erythematosus (SLE). Started Oct 2024; status: recruiting.
02
Drugs
JY231
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06675422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06675422.